Are All Low Molecular Weight Heparins Equivalent in the Management of Venous Thromboembolism?
Open Access
- 26 December 2007
- journal article
- review article
- Published by SAGE Publications in Clinical and Applied Thrombosis/hemostasis
- Vol. 14 (4), 385-392
- https://doi.org/10.1177/1076029608319881
Abstract
Low molecular weight heparins are replacing unfractionated heparin in a number of clinical indications because of their improved subcutaneous bioavailability and more predictable antithrombotic response. Clinical trials have demonstrated that low molecular weight heparins are at least as safe and effective as unfractionated heparin for the initial treatment of venous thromboembolism, and unfractionated heparin and warfarin for primary and secondary thromboprophylaxis. The mechanism behind the antithrombotic action of low molecular weight heparins is not fully understood but is likely to involve inhibition of coagulation factors Xa and IIa (thrombin), release of tissue-factor-pathway inhibitor, and inhibition of thrombin activatable fibrinolytic inhibitor. Different low molecular weight heparins have been shown to have various effects on coagulation parameters. Seven low molecular weight heparins are currently marketed worldwide, each demonstrated distinct chemical entities with unique pharmacokinetic and pharmacodynamic profiles. Each low molecular weight heparin is approved for specific indications based on the available efficacy and safety data for that product. The relative efficacy and safety of the low molecular weight heparins are unclear because there have been very few direct comparisons in randomized clinical trials. While recommending low molecular weight heparins for the prevention and treatment of venous thromboembolism, clinical guidelines have not specified individual agents. National and international organizations recognize that low molecular weight heparins are distinct entities and that they should not be used interchangeably in clinical practice. Each low molecular weight heparin should be used at the recommended dose when efficacy and safety data exist for the condition being treated. When these data are not available, the dosing and administration of low molecular weight heparins must be adapted from existing data and recommendations.Keywords
This publication has 45 references indexed in Scilit:
- Product Individuality of Commercially Available Low-Molecular-Weight Heparins and Their Generic Versions: Therapeutic ImplicationsClinical and Applied Thrombosis/hemostasis, 2006
- Meta-Analysis: Low-Molecular-Weight Heparin and Bleeding in Patients with Severe Renal InsufficiencyAnnals of Internal Medicine, 2006
- Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgeryBritish Journal of Surgery, 2001
- For the Initial Treatment of Venous Thromboembolism: Are All Low-molecular-weight Heparin Compounds the Same?Thrombosis Research, 2000
- A Meta-analysis Comparing Low-Molecular-Weight Heparins With Unfractionated Heparin in the Treatment of Venous ThromboembolismArchives of Internal Medicine, 2000
- Low-Molecular-Weight Heparins Compared with Unfractionated Heparin for Treatment of Acute Deep Venous ThrombosisAnnals of Internal Medicine, 1999
- Heparin and Low-Molecular-Weight HeparinSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 1998
- The Available Low Molecular Weight Heparin Preparations Are Not the SameClinical and Applied Thrombosis/hemostasis, 1997
- Low-Molecular-Weight HeparinsThe New England Journal of Medicine, 1997
- HeparinThe New England Journal of Medicine, 1991